The headlines announcing the results of a phase III clinical trial (ECOG-ACRIN 2108) stated that radiation and surgery to the breast–also called locoregional therapy (LRT)– for people with de novo metastatic breast cancer did not increase survival. However, despite the headlines, the common practice is still to decide on a case-by-case basis if locoregional therapy to the breast ought to be given after a diagnosis of metastatic disease. This approach to using LRT continues because there are still unanswered questions and ongoing research.
See below for links discussing the trial, remaining research questions and other reasons someone might choose LRT.
- Surgery and Radiation do not Extend Survival in Newly Diagnosed Metastatic Breast Cancer Data from the recent ECOG-ACRIN 2108 trial suggests that LRT for de novo MBC does not increase survival.
- Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial Researchers note that since survival rates for both groups were higher than expected at 3 years, a longer trial may be needed to evaluate LRT.
- Locoregional Therapy of the Primary Tumor in De Novo Stage IV Breast Cancer in 216066 Patients: A Meta-Analysis After reviewing journal articles on LRT and de novo MBC, these researchers give a thorough discussion of who may benefit from LRT, and theories on why it may increase survival.
- Surgery for Metastatic Breast Cancer Fails to Boost Overall Survival Researchers are studying if LRT for people with a subset of de novo MBC–oligometastatic breast cancer–increases survival.
- When to Consider Local Therapy for Stage IV Breast Cancer An overview of the research about LRT for metastatic breast cancer, including when to consider breast surgery for reasons other than increasing survival.